J&J's Magnificent Seven: Aging Blockbusters Carry Firm As New Launches Come Along
This article was originally published in The Pink Sheet Daily
Executive Summary
With only three of its seven listed blockbusters growing and manufacturing troubles weighing heavily, J&J predicts modest '11 growth, then acceleration.
You may also be interested in...
Generics For Risperdal Consta Need Multi-Dose Testing, J&J Argues
Citizen petition tells FDA not to worry about bioequivalence tests in fasting patients, but focus on the product's three-stage release characteristics.
Generics For Risperdal Consta Need Multi-Dose Testing, J&J Argues
Citizen petition tells FDA not to worry about bioequivalence tests in fasting patients, but focus on the product's three-stage release characteristics.
Johnson & Johnson Plans Move Into Vaccines With Bid For Remainder Of Crucell
Deal could position the pharma giant to eventually become a sixth major player in the worldwide vaccine space.